This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Fovea Pharmaceuticals. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Jacques Le Roux: Innovator in Kinase-Mediated Disorder Treatments
Introduction
Jacques Le Roux is a notable inventor based in Le Pre Saint Gervais, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target kinase-mediated disorders. His work has the potential to impact various medical conditions, including cardiovascular diseases and cancer.
Latest Patents
Jacques Le Roux holds 1 patent for his invention titled "Substituted quinazoline compounds." This invention focuses on novel compounds that serve as selective kinase inhibitors. The methods associated with these compounds aim to treat or ameliorate a range of kinase-mediated disorders, including diabetes, inflammatory diseases, and diseases of the eye such as retinopathies.
Career Highlights
Le Roux is currently associated with Fovea Pharmaceuticals, where he continues to innovate in the pharmaceutical industry. His expertise in developing kinase inhibitors has positioned him as a key figure in the research and treatment of complex medical conditions.
Collaborations
Throughout his career, Jacques has collaborated with talented professionals, including Caroline Leriche and Eric Auclair. These partnerships have enhanced his research and contributed to the advancement of therapeutic solutions.
Conclusion
Jacques Le Roux's work in developing substituted quinazoline compounds exemplifies the innovative spirit of modern inventors. His contributions to treating kinase-mediated disorders highlight the importance of research in improving healthcare outcomes.